TSLA
Tesla
-- 423.880 NVDA
NVIDIA
-- 136.880 PLTR
Palantir
-- 73.965 AMD
Advanced Micro Devices
-- 129.915 GOOG
Alphabet-C
-- 194.640 
NEWS
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
• Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset
• Zelicapavir was well-tolerated with a favorable safety profile
• Conference call and webcast to discuss data at 8:30 a.m. ET today
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset
• Zelicapavir was well-tolerated with a favorable safety profile
• Conference call and webcast to discuss data at 8:30 a.m. ET today
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
pistol bluff : wtf